Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.

MLA

Ducreux, Michel, et al. “Bevacizumab Combined with 5-FU/Streptozocin in Patients with Progressive Metastatic Well-Differentiated Pancreatic Endocrine Tumours (BETTER Trial)--a Phase II Non-Randomised Trial.” European Journal of Cancer (Oxford, England : 1990), vol. 50, no. 18, Dec. 2014, pp. 3098–106. EBSCOhost, https://doi.org/10.1016/j.ejca.2014.10.002.

APA

Ducreux, M., Dahan, L., Smith, D., O’Toole, D., Lepère, C., Dromain, C., Vilgrain, V., Baudin, E., Lombard-Bohas, C., Scoazec, J.-Y., Seitz, J.-F., Bitoun, L., Koné, S., & Mitry, E. (2014). Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial. European Journal of Cancer (Oxford, England : 1990), 50(18), 3098–3106. https://doi.org/10.1016/j.ejca.2014.10.002

Chicago

Ducreux, Michel, Laetitia Dahan, Denis Smith, Dermot O’Toole, Céline Lepère, Clarisse Dromain, Valérie Vilgrain, et al. 2014. “Bevacizumab Combined with 5-FU/Streptozocin in Patients with Progressive Metastatic Well-Differentiated Pancreatic Endocrine Tumours (BETTER Trial)--a Phase II Non-Randomised Trial.” European Journal of Cancer (Oxford, England : 1990) 50 (18): 3098–3106. doi:10.1016/j.ejca.2014.10.002.